

MusclePharm Corp
Form 8-K
December 13, 2018

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

December 7, 2018
Date of report (date of earliest event reported)

MusclePharm Corporation
(Exact name of registrant as specified in its charter)

| | | |
|--|-----------------------------|--|
| Nevada | 000-53166 | 77-0664193 |
| (State or other jurisdictions of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Nos.) |

4400 Vanowen Street, Burbank, CA 91505
(Address of principal executive offices) (Zip Code)

(303) 396-6100
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Edgar Filing: MusclePharm Corp - Form 8-K

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2018 Annual Meeting of Stockholders (the “Annual Meeting”) of MusclePharm Corporation (the “Company”) was held on December 7, 2018. A total of 10,305,700 shares of the Company’s common stock were present at the meeting in person or by proxy, which represented 67% of the shares entitled to vote, and which constituted a quorum for the transaction of business. The matters presented for a vote and the related results are as follows:

1. Election of Directors

Proposal one was the election of four nominees to serve as directors of the Company until the next annual meeting of stockholders and until their respective successors have been elected and qualified, or until their earlier resignation, removal or death. The results of the vote were as follows:

| Nominee | Votes For | Votes Against | Abstain | Broker Non-Votes |
|-----------------|-----------|---------------|---------|------------------|
| Ryan Drexler | 3,286,666 | 3,092,101 | 1,819 | 3,925,114 |
| John J. Desmond | 3,324,486 | 3,036,412 | 19,688 | 3,925,114 |
| William J. Bush | 3,324,477 | 3,036,421 | 19,688 | 3,925,114 |
| Brian Casutto | 3,287,454 | 3,072,832 | 20,300 | 3,925,114 |

Pursuant to the foregoing votes, the four nominees listed above were elected to serve on the Company’s Board of Directors for a term expiring at the 2019 annual meeting of stockholders. There were no additional director nominations brought before the Annual Meeting.

2. Ratification of the Independent Registered Public Accountants

Proposal two was the ratification of the appointment of Plante & Moran, PLLC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018. The results of the vote were as follows:

| For | Against | Abstain |
|-----------|-----------|---------|
| 6,467,743 | 3,770,625 | 67,332 |

Pursuant to the foregoing vote, the ratification of Plante & Moran, PLLC as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2018 was approved.

3. Advisory, Non-Binding Vote on the Compensation of Named Executive Officers

Proposal three was the approval, on a non-binding, advisory basis, the compensation paid to the Company’s named executive officers as described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on October 26, 2018. The results of the vote were as follows:

| For | Against | Abstain | Broker Non-Votes |
|-----------|-----------|---------|------------------|
| 3,289,817 | 3,085,415 | 5,354 | 3,925,114 |

Pursuant to the foregoing vote, on a non-binding, advisory basis, the compensation paid to the Company's named executive officers, was approved.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MUSCLEPHARM
CORPORATION

By: /s/ Ryan Drexler
Name: Ryan
Drexler
Title: Chief
Executive Officer
and
President

Date: December 13, 2018